Researchers found that patients who newly used drugs for hot flashes shortly after AHT initiation had worse disease-free survival and a higher treatment discontinuation rate.
Contrary to results from clinical trials, a population-based study found worse disease-free survival among patients who experience adjuvant hormone therapy–related hot flashes.